Celularity SG&A Expenses 2019-2024 | CELU

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Celularity sg&a expenses from 2019 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Celularity sg&a expenses from 2019 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$150.5B
Bristol Myers Squibb (BMY)	$118.1B
Vertex Pharmaceuticals (VRTX)	$115.4B
Gilead Sciences (GILD)	$109.4B
CSL (CSLLY)	$85.4B
Regeneron Pharmaceuticals (REGN)	$81.8B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$34.4B
Alnylam Pharmaceuticals (ALNY)	$30.2B
BioNTech SE (BNTX)	$25.5B
Biogen (BIIB)	$22.6B
Illumina (ILMN)	$21.4B
BeiGene (BGNE)	$18.3B
Moderna (MRNA)	$14.3B
Incyte (INCY)	$13.6B
Genmab (GMAB)	$13.6B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$11.8B
Vaxcyte (PCVX)	$10.9B
Bio-Techne Corp (TECH)	$10.5B
Sarepta Therapeutics (SRPT)	$10.2B
Exact Sciences (EXAS)	$10B
Exelixis (EXEL)	$9.8B
Revolution Medicines (RVMD)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
QIAGEN (QGEN)	$9.3B
Intra-Cellular Therapies (ITCI)	$8.8B
Roivant Sciences (ROIV)	$8.4B
Ascendis Pharma (ASND)	$7.5B
Repligen (RGEN)	$7.2B